2.1 Pharmacokinetic & Pharmacodynamic Principles

Pharmacokinetic & Pharmacodynamic Principles

Introduction to Pharmacokinetics in Critical Care

Pharmacokinetics (PK) describes the movement of drugs through the body, mathematically described by four primary processes: Absorption, Distribution, Metabolism, and Excretion (ADME). Understanding these principles is absolutely essential for the Acute Care Nurse Practitioner (AGACNP) when prescribing and dosing medications in critically ill patients. In the intensive care unit (ICU), physiological instability profoundly alters drug disposition, rendering standard dosing regimens ineffective or potentially toxic.

Absorption and Bioavailability Considerations

Absorption describes the transfer of a drug from its site of administration into the systemic circulation. Bioavailability (F) is the fraction of the administered dose that reaches the systemic circulation in an unchanged, active form. Intravenous (IV) medications inherently have a bioavailability of 100% (F=1), whereas enteral or oral medications often have significantly reduced bioavailability due to incomplete gastrointestinal absorption and first-pass metabolism in the liver.

In the acute care setting, normal absorption is frequently compromised. Conditions such as gastrointestinal dysmotility, ileus, splanchnic hypoperfusion from shock states, and the administration of continuous vasopressor infusions can severely impair the absorption of enterally administered drugs. Furthermore, gastric pH alterations from stress ulcer prophylaxis (e.g., proton pump inhibitors, H2 receptor antagonists) can affect the ionization and subsequent absorption of certain medications. Therefore, the IV route is heavily preferred for life-saving interventions and resuscitations, ensuring rapid and predictable systemic delivery.

Distribution and Volume of Distribution (Vd)

Distribution involves the reversible transfer of a drug between the intravascular blood volume and extravascular tissues. The Volume of Distribution (Vd) is a critical theoretical pharmacokinetic parameter. It quantifies the extent to which a drug distributes into body tissues rather than remaining in the plasma. A high Vd indicates extensive tissue distribution, typical for highly lipophilic drugs (e.g., amiodarone, propofol, fentanyl). Conversely, a low Vd indicates the drug is primarily confined to the intravascular space, common for highly protein-bound or hydrophilic drugs (e.g., beta-lactam antibiotics, aminoglycosides).

Critically ill patients universally experience significant fluid shifts, such as third-spacing due to sepsis, severe burns, major abdominal surgery, or aggressive crystalloid resuscitation. This massively expands the extracellular fluid compartment. As a result, the Vd for hydrophilic drugs dramatically increases, which can dilute the drug concentration in the plasma. For the AGACNP, this necessitates the administration of significantly higher initial loading doses for hydrophilic medications to quickly achieve and maintain therapeutic plasma concentrations.

Furthermore, profound hypoalbuminemia is ubiquitous in malnutrition, hepatic dysfunction, or systemic inflammation. Albumin is the primary binding protein for many acidic drugs (e.g., phenytoin, valproic acid). A reduction in serum albumin decreases the protein binding capacity, leading to an increased fraction of unbound, pharmacologically active drug (free drug). Because standard laboratory assays typically measure total drug concentration (bound plus unbound), a normal total level in the setting of hypoalbuminemia may actually mask a toxic free drug concentration.

Metabolism and Hepatic Clearance

Metabolism is the enzymatic biotransformation of a parent drug into active or inactive metabolites. This process primarily occurs in the liver via the Cytochrome P450 (CYP450) enzyme system. Metabolism is divided into Phase I reactions (oxidation, reduction, hydrolysis), which typically make drugs more polar, and Phase II reactions (conjugation, such as glucuronidation), which attach large endogenous molecules to further increase aqueous solubility, facilitating renal excretion.

Drug-drug interactions in the ICU frequently manifest at the level of CYP450 metabolism. Enzyme inducers (e.g., rifampin, phenytoin, phenobarbital) accelerate the metabolism of concurrent medications, potentially leading to subtherapeutic levels and therapeutic failure. Enzyme inhibitors (e.g., amiodarone, fluconazole, diltiazem, macrolides) reduce metabolic activity, leading to drug accumulation and increasing the risk of severe toxicity.

Hepatic hypoperfusion, often termed "shock liver," secondary to cardiogenic or septic shock, abruptly decreases the delivery of drugs to hepatic enzymes, acutely impairing clearance. This requires immediate reassessment of maintenance dosing for hepatically cleared medications.

Excretion and Renal Clearance

Clearance (Cl) is the volume of plasma completely cleared of a drug per unit time. Total body clearance is the sum of hepatic, renal, and other clearance mechanisms (e.g., biliary, pulmonary). The kidneys are the primary organ for excretion of unchanged drugs and hydrophilic metabolites.

Acute kidney injury (AKI) is a frequent complication of critical illness, leading to significantly reduced renal clearance. This demands meticulous maintenance dose reductions or extended dosing intervals to prevent dangerous drug accumulation. Conversely, early hyperdynamic stages of sepsis, trauma, or burns can induce Augmented Renal Clearance (ARC). ARC is characterized by supranormal glomerular filtration rates (e.g., creatinine clearance > 130 mL/min), which dramatically accelerates the elimination of renally cleared drugs. In ARC, standard dosing leads to therapeutic failure, necessitating increased doses, shorter dosing intervals, or continuous infusions.

Continuous Renal Replacement Therapy (CRRT), frequently utilized in hemodynamically unstable patients, adds another layer of complexity. Drug removal via CRRT depends on the drug's molecular weight, degree of protein binding, Vd, and the specific CRRT modality (CVVH, CVVHD, CVVHDF) and flow rates utilized. Highly protein-bound drugs or those with a very large Vd are generally not significantly removed by CRRT.

Half-Life, Steady State, and Pharmacodynamics

Half-life (t1/2) is the time required for the plasma concentration of a drug to decrease by exactly 50%. It is directly proportional to Vd and inversely proportional to clearance (t1/2 = 0.693 * Vd / Cl). It takes approximately 4 to 5 half-lives for a drug to reach steady state (where the rate of drug administration perfectly matches the rate of elimination) during a continuous fixed dosing regimen. Similarly, it takes 4 to 5 half-lives for a drug to be almost entirely eliminated after discontinuation.

Pharmacodynamics (PD) describes the biochemical and physiologic effects of the drug on the body, encompassing receptor binding, signal transduction, and the ultimate clinical response. The relationship between drug concentration and its effect is non-linear and is often described by the maximum effect (Emax) and the concentration required to achieve 50% of that maximum effect (EC50). Downregulation or desensitization of receptors can occur with prolonged agonist exposure (e.g., beta-agonists in asthma), while upregulation can occur with prolonged antagonist exposure (e.g., beta-blocker withdrawal leading to rebound tachycardia).

Clinical Application Table: PK Alterations in ICU